Anandamide contracts main bronchi and relaxes mesenteric arteries via activation of vanilloid receptors. A, the vanilloid receptor antagonist capsazepine (3 M), but not the CB1 receptor antagonist SR141716A (300 nM), inhibited contractions induced by anandamide in main bronchi (n ϭ 4 -5). The effects of capsazepine and SR141716A were studied in the presence of the FAAH inhibitor PMSF (100 M), which by itself did not significantly potentiate contractions to anandamide (n ϭ 6). B, capsazepine (300 nM) caused a rightward shift of the anandamide concentration-response curve in mesenteric arteries (n ϭ 6). Traces show the inability of the cannabinoid receptor agonists HU-210 and WIN 55212-2 to mimic the action of anandamide in main bronchi (A) and mesenteric arteries (B). Data are expressed as mean Ϯ S.E.M. (*, P Ͻ 0.05 compared with PMSF alone.)
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